Rights, preferences and restrictions attached to equity shares
The Company has only one class of equity share with face value of ' 10 per share. Each holder of equity share is entitled to one vote per share. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend.
F) The Company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) during the year.
G) There are no bonus shares issued or shares issued for consideration other than cash or shares bought back during five years preceding 31st March, 2026.
Nature and Purpose of Reserves:
(i) Securities Premium
Securities premium represents the premium on issue of shares. This balance can be utilised in accordance with the provisions of the Companies Act, 2013.
(ii) General Reserve
General reserve represents accumulated profits and is created by transfer of profits from retained earnings and it is not an item of other comprehensive income.
(iii) Retained Earnings
Retained earnings are the profits that the Company has earned till date, less any transfer to general reserves & dividend.
Terms & Conditions for long-term secured borrowings from Banks: The Company has availed fully secured term loan of ' 2,620 Million (Sanctioned amount ' 3,500 Millions) (P.Y. ' 750 Millions) from HDFC Bank Ltd. bearing interest rate of Repo rate plus 200 bps, repayable in 180 monthly installments starting from April 2025 till March 2040. The Facility is secured by (i) Exclusive mortgage and charge on Borrower's immovable properties pertaining to Dombivali hospital; (ii) Exclusive charge by way of hypothecation on all Borrower's tangible movable assets, pertaining to Dombivali hospital. (iii) A second pari passu charge on all Borrower's current assets and receivables.
NOTE 36 FINANCIAL RISK
The Company's activities expose it to various financial risks, including market risk, credit risk and liquidity risk. The Company's risk management assessment and policies and processes are established to identify and analyse the risks faced by the Company by setting appropriate limits and controls and monitoring such risks. The policies and processes are reviewed regularly to reflect changes in market conditions and the Company's activities.
Credit risk - is the risk of loss that may arise on outstanding financial instruments if a counterparty default on its obligations. The Company's exposure to credit risk arises majorly from trade receivables and other financial assets. Other financial assets are bank deposits with banks and hence, the Company does not expect any credit risk with respect to these financial assets. With respect to other financial assets, the Company has constituted teams to review the receivables on periodic basis and to take necessary mitigations, wherever required. The Company creates allowance for all unsecured receivables based on lifetime expected credit loss. At the balance sheet date, there was no significant concentration of credit risk and exposure thereon. Liquidity risk - is the risk that the Company will not be able to meet the financial obligations as they become due. The Company manages its liquidity risk by ensuring, as far as possible, that it will have sufficient liquidity to meet its liabilities when due, under both, normal and stressed conditions, without incurring unacceptable losses or risk to the Company's reputation. With significant investments in fixed deposits, cash in hand and available borrowing lines, the Company does not envisage any material effect on its liquidity.
Market risk - is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risks: interest rate risk, currency risk and other price risk. Financial instruments affected by market risk includes investments, trade payables, trade receivables and loans.
Foreign currency risk - is the risk that the fair value or future cash flows of an exposure will fluctuate due to changes in foreign exchange rates. The Company does not have any material foreign currency exposure.
Interest rate risk - is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to the Company's long term debt obligation at floating interest rates.
Interest rate Sensitivity of Borrowings
With all other variables held constant, the following table demonstrates the sensitivity to a reasonably possible change in interest rates on floating rate portion of loans and borrowings.
NOTE 37 OTHER ADDITIONAL NOTES FORMING PART OF FINANCIAL STATEMENT 37.A Exceptional Item
On 21st November, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws ('New Labour Codes'). The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed the financial implications of the changes arising from the implementation of the New Labour Codes in accordance with the guidance issued by the Institute of Chartered Accountants of India and based on actuarial valuation whch has resulted in increase in the gratuity liability arising out of past service cost by ' 43.89 Millions (net of subsequent reversal upon actualisation of charge). Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Company has presented this incremental amount under "Exceptional Items" in the standalone financial results for the quarter and year ended 31st March, 2026.
*Out of various pending litigations, it is possible but not probable that outflow of money would be required to settle the matter.
The Company has taken the adequate insurance of ' 250 Million towards such matter arises if any.
The Company does not expect the outcome of the matters stated above to have material adverse impact on the Company's financial condition, results of operation or cash flows.
Future cash outflows, if any, in respect of above are determinable only on receipt of judgement/decisions pending at various forums/ authorities or final outcome of matter.
**Appeal filed with Commissioner (Appeals) -Thane - Hearing Concluded- Final Order issued- Tax Demand to the tune of ' 8.36 Million has been dropped by the Commissioner (Appeals) and has confirmed the demand of ' (4.54) Million. Out of which Company has paid undisputed tax to the tune of ' 0.12 Million.And for Disputed Tax demand of ' 4.42 Million the Company has filed Appeal before Customs Excise and Service Tax Appellate Tribunal (CESTAT) Mumbai - A hearing has not yet been scheduled.
During the year under review, the Company has provided a corporate guarantee in favour of HDFC Bank Limited for the borrowing availed by Jupiter Hospital Projects Private Limited (JHPPL), its material subsidiary, for an amount not exceeding ' 2,500 Million.The Company's guarantee shall be released upon either the repayament/pre-payment of 50% of the facility availed by JHPPL, or upon JHPPL achieving a Debt/EBITDA < 3.5x for four consecutive quarters.
37.C Gratuity
The employees' gratuity scheme is a unfunded defined benefit plan. The present value of obligation is determined based on actuarial valuation using the projected unit credit method, which recognises each period of service as giving rise to additional unit of employee benefit entitlement and measures each unit separately to build up the final obligation. The obligation for leave encashment is recognised in the same manner as gratuity.
(xii) Gratuity recognised as an expense and included in Note 29 under "Employee benefits expense" is ' 15.36 Million (' 12.43 Million)
(xiii) Leave encashment recognised as an expense and included in Note 29 under "Employee benefits expense" is ' 16.49 Million (' 9.01 Million).
(xiv) The estimate of future salary increase in the actuarial valuation is considered after taking into account the rate of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.
(xv) Contribution to provident and other funds is recognised as an expense in Note 29 of the financial statements.
37.D Investment in subsidiaries and firms
The Company has invested in Jupiter Hospital Projects Private Limited holding 96.56% stake as on 31st March, 2026. The total paid up capital of the Company consists of ' 800 Million Equity Shares capital out of which the Company is holding ' 772.5 Million Equity share capital.
The Company has invested in Medulla Healthcare Private Limited holding 100% stake as on 31st March, 2026. The total paid up capital of the Company consists of ' 1 Lakhs Equity Shares capital.
The Company holds 95% stake in Jupiter Hospital Pharmacy Private Limited as on 31st March, 2026. The total paid up capital of the Company consists of ' 1 Lakhs Equity Shares capital.
37.H Capital Management
For the purpose of the Company's Capital Management, capital includes issued capital and other equity reserves, long term funds attributable to the Equity Shareholders of the Company. The primary objective of the Company's Capital Management is to maximise shareholders value and keep the debt equity ratio within acceptable range. The Company manages its capital structure and makes adjustments in the light of changes in economic environment and the requirements of the financial covenants. The Company monitors capital using adjusted net debt to equity ratio. For this purpose, adjusted net debt is defined as total debt less cash and bank balances.
37.M Segment reporting
The chief operating decision maker (CODM) examines the Company's performance from a service perspective and has identified the Healthcare services as a single business segment. The Company is operating in India which constitutes a single geographical segment. Hence, as per Ind AS-108 Operating Segments issued by the Institute of Chartered Accountants of India, no separate disclosure on segment information is given in these financial statements.
37.N Scheme of arrangement/amalgamation
The proposed merger of Medulla Healthcare Private Limited ("Transferor Company"), a direct wholly-owned subsidiary of Jupiter Life Line Hospitals Limited ("Transferee Company") with the Transferee Company with effect from 1st April, 2025 is pending final sanction of the Honourable National Company Law Tribunal, Mumbai. Thus, effect of the proposed scheme (being not material) is not given in the current financial statements of the Transferee Company.
37.O Dividend
After the close of financial year, the Board of Directors at their meeting held on 15th May, 2026 declared an interim dividend of ' 1 per share for the financial year 2025-26.
37.P Additional regulatory information not disclosed elsewhere in the financial information
a) There are no properties/assets which are not held or registered in the name of the Company (benami property), other than those disclosed in this financial information.
b) Transactions and balances with companies which have been removed from register of Companies [struck off companies] as at the above reporting periods is Nil.
c) The Company has not traded/invested in Crypto currency.
d) The Company does not have any charges or satisfaction which is yet to be registered with Registrar of Companies beyond the statutory period.
e) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
Except as disclosed in Financial Statement of the subsidiary companies and firms.
f) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
i. directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
ii. provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries,
g) The Company has no such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).
h) The Company is not a declared wilful defaulter by any bank or financial Institution or other lender.
i) As at 31st March, 2026, there are no standards that have been issued but are not yet effective, which will impact this financial information.
37.Q As per the requirements of rule 3(1) of the Companies (Accounts) Rules 2014 the Company uses only such accounting software's for maintaining its books of account that have a feature of recording audit trail; except for certain instances where audit trail feature was not enabled at its database level. However, the Company established and maintained an adequate internal control framework over its financial reporting and based on its assessment, has concluded that the internal controls for the year ended 31st March, 2026 were operating effectively.
37.R Figures have been rounded off to the nearest rupees (?) in Million up to two decimal places (except for EPS and Nos of Shares). Previous year's figures have been regrouped wherever applicable to facilitate comparability.
|